Page last updated: 2024-08-24

mibefradil and Disease Exacerbation

mibefradil has been researched along with Disease Exacerbation in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baxter, GF; Gadgil, S; Mocanu, MM; Yellon, DM	1

Other Studies

1 other study(ies) available for mibefradil and Disease Exacerbation

Article	Year
Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism. Cardiovascular drugs and therapy, 1999, Volume: 13, Issue:2 Topics: Animals; Benzimidazoles; Calcium Channel Blockers; Disease Progression; Enzyme Activation; Glyburide; Hemodynamics; In Vitro Techniques; Ischemic Preconditioning, Myocardial; Male; Mibefradil; Myocardial Infarction; Protein Kinase C; Rats; Rats, Sprague-Dawley; Risk Factors; Tetrahydronaphthalenes	1999

Article

Year

Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism.

Cardiovascular drugs and therapy, 1999, Volume: 13, Issue:2

Topics: Animals; Benzimidazoles; Calcium Channel Blockers; Disease Progression; Enzyme Activation; Glyburide; Hemodynamics; In Vitro Techniques; Ischemic Preconditioning, Myocardial; Male; Mibefradil; Myocardial Infarction; Protein Kinase C; Rats; Rats, Sprague-Dawley; Risk Factors; Tetrahydronaphthalenes

1999